Attgeno develops novel nitric oxide donators which are selective for the pulmonary circulation, making them safe and without systemic side-effects.Attgeno has developed Supernitro, a first in class therapy for the specific delivery of Nitric Oxide (NO) in the lung for prevention and treatment of pulmonary hypertension. By the donation of NO in the lungs, Supernitro replaces the decrease in NO production that is a well-known consequence of different diseases leading to increased risk for pulmonary hypertension, a condition associated with severe morbidity and mortality.
Eir Ventures joins oversubscribed investment round in Attgeno
